Search results
Results from the WOW.Com Content Network
284.9 Aplastic anemia unspecified; 285 Other and unspecified anemias. 285.0 Sideroblastic anemia; 285.1 Acute posthemorrhagic anemia; 285.2 Anemia in chronic illness. 285.21 Anemia in chronic kidney disease; 285.22 Anemia in neoplastic disease; 285.29 Anemia of other chronic illness; 285.3 Antineoplastic chemotherapy induced anemia; 285.8 Other ...
Anemia of chronic disease may also be due to neoplastic disorders and non-infectious inflammatory diseases. [6] Neoplastic disorders include Hodgkin disease and lung and breast carcinoma, while non-infectious inflammatory diseases include celiac disease, [10] rheumatoid arthritis, systemic lupus erythematosus, scleroderma and dermatomyositis.
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
ICD-10 coding number Diseases Database coding number Medical Subject Headings Iron-deficiency anemia: D50: 6947: Iron-deficiency anemia (or iron deficiency anaemia) is a common anemia that occurs when iron loss (often from intestinal bleeding or menses) occurs, and/or the dietary intake or absorption of iron is insufficient. In such a state ...
About 10% of individuals with BPDCN present with a leukemia-like disease, [4] i.e. they exhibit circulating malignant pDC, anemia, thrombocytopenia, and/or leukopenia due to extensive malignant pDC infiltrations in the bone marrow. [4] A leukemic phase of the disease is a common feature of end stage and post-therapy relapsing BPDCN. [2]
Other pre-existing bone-marrow disorders such as acquired aplastic anemia following immunosuppressive treatment and Fanconi anemia can evolve into MDS. [15] MDS is thought to arise from mutations in the multipotent bone-marrow stem cell, but the specific defects responsible for these diseases remain poorly understood.
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7]
[9] [10] Acute erythroid leukemia (M6) has a relatively poor prognosis. A 2010 study of 124 patients found a median overall survival of 8 months. [10] A 2009 study on 91 patients found a median overall survival for erythroleukemia patients of 36 weeks, with no statistically significant difference to other AML patients.